A putative therapeutic target in renal cell carcinoma: Q15831

Ablatotech Signals reports today on a putative therapeutic target — Q15831 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in renal cell carcinoma.

Background

The putative target Q15831, also known as the protein encoded by the gene associated with renal cell carcinoma (RCC), emerges as a candidate for further exploration in the context of this malignancy. Preliminary findings from expression-profiling studies indicate a potential role for Q15831 in RCC, yet it remains uncharacterized in clinical applications, with no registered Phase 1 or higher clinical programs. This underscores the need for a comprehensive investigation into its therapeutic implications and biological relevance in renal cancer.

Data-mining rationale

The rationale for investigating Q15831 is rooted in a systematic data-mining approach that involved cross-referencing UniProt's reviewed human entries related to "renal cell carcinoma" against a substantial collection of 295 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, Q15831 was identified in several expression-profiling studies, suggesting its potential involvement in RCC. However, the absence of clinical programs highlights the necessity for further validation of its role in this disease.

Why prior analyses may have missed this

Prior analyses may have overlooked Q15831 due to the limitations inherent in earlier microarray datasets, many of which were generated before the adoption of modern statistical techniques, such as empirical-Bayes methods exemplified by limma. These earlier datasets often lacked appropriate multiple-testing corrections, which may have hindered the identification of significant expression changes associated with Q15831. Consequently, the potential relevance of this candidate in RCC may not have been adequately characterized.

Reasoning for further validation

To elucidate the potential role of Q15831 in renal cell carcinoma, several experimental approaches are warranted:

1. **Re-analyze matched GEO datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set at < 0.05 to identify differentially expressed genes, including Q15831, in a more statistically robust manner.

2. **Validate expression levels**: Conduct quantitative PCR (qPCR) on independent cohorts of RCC samples to confirm the differential expression of Q15831 and assess its correlation with clinical parameters.

3. **Assess tissue specificity**: Leverage resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to evaluate the tissue-specific expression of Q15831, which may provide insights into its functional relevance in RCC.

4. **Explore pathway context**: Implement bioinformatics tools like STRING and OmniPath to investigate the potential pathways and interactions involving Q15831, thereby elucidating its role in the tumor biology of RCC.

5. **Evaluate druggability**: If validation of Q15831's expression and function is achieved, assess its druggability using databases such as DGIdb and ChEMBL to explore potential therapeutic interventions targeting this candidate.

References

[UniProt: Q15831](https://www.uniprot.org/uniprot/Q15831)
[NCBI GEO](https://www.ncbi.nlm.nih.gov/geo/)
[Limma: Linear Models for Microarray Data](https://bioconductor.org/packages/release/bioc/html/limma.html)
[GTEx Project](https://gtexportal.org/home/)
[Human Protein Atlas](https://www.proteinatlas.org/)
[STRING Database](https://string-db.org/)
[OmniPath](https://omnipathdb.org/)
[DGIdb](http://www.dgidb.org/)
[ChEMBL](https://www.ebi.ac.uk/chembl/)

References